OUR SCIENCE
What we develop
Introducing MultiTEP: A Breakthrough in Neurodegenerative Disease Research
Our multidisciplinary team at Nuravax has developed an innovative vaccine platform, MultiTEP, specifically tailored for neurodegenerative disorders like Alzheimer’s Disease (AD). MultiTEP is a universal, highly immunogenic recombinant protein vaccine, uniquely designed to generate high concentrations of antibodies against pathological molecules involved in AD and PD.
The platform integrates promiscuous foreign T-helper (Th) epitopes from various pathogens, along with a synthetic Th epitope, PADRE. This composition ensures broad coverage of human MHC polymorphisms, effectively activating both naive Th cells and pre-existing memory Th cells. These cells may have been previously primed by conventional vaccines or infections throughout an individual’s life.
Our preclinical studies with MultiTEP have shown outstanding results. The platform demonstrates high immunogenicity, successfully generating robust antibody responses in mice, rabbits, and non-human primates. This represents a significant stride forward in the quest for effective treatments for neurodegenerative diseases.
The platform integrates promiscuous foreign T-helper (Th) epitopes from various pathogens, along with a synthetic Th epitope, PADRE. This composition ensures broad coverage of human MHC polymorphisms, effectively activating both naive Th cells and pre-existing memory Th cells. These cells may have been previously primed by conventional vaccines or infections throughout an individual’s life.
Our preclinical studies with MultiTEP have shown outstanding results. The platform demonstrates high immunogenicity, successfully generating robust antibody responses in mice, rabbits, and non-human primates. This represents a significant stride forward in the quest for effective treatments for neurodegenerative diseases.
B cell-oriented antigen
T cell-oriented antigen
Universal MultiTEP platform
We use three copies of target epitopes for better antibody production.
MultiTEP provides a robust, broad T helper signal and significantly increases antibody production to harmful proteins.
We also in-licensed a novel, highly immunogenic adjuvant to give a super boost to antibody generation.
Adjuvant
The B cell epitopes from disease-related pathological molecules attached to this universal vaccine platform allow us to generate a recombinant protein vaccine producing high titers of therapeutic antibodies.
Based on what we observed in aged non-human primates, we believe MultiTEP may be especially beneficial in elderly people.
01.
Target not only naïve, but also pre-existing memory Th cells specific to pathogens that most adults would have either been exposed to or vaccinated against, and taking advantage of the high levels of memory Th cells overcome immunosenescence in the elderly
Avoid the generation of harmful autoreactive T cells (e.g., specific to self Aβ, tau, α-syn, etc.)
Activate a broad repertoire of Th cells providing broad coverage of the targeted population with high MHC class II gene polymorphism
02.
03.
04.
Alzheimer’s Stages
Nuravax Vaccines
40 — 55 years old
55 — 60 years old
65 — 75 years old
Overcome self-tolerance by activating T helper (Th) cells specific to mixed foreign epitopes incorporated in MultiTEP
Target not only naïve, but also pre-existing memory Th cells specific to pathogens that most adults would have either been exposed to or vaccinated against, and taking advantage of the high levels of memory Th cells overcome immunosenescence in the elderly
Avoid the generation of harmful autoreactive T cells (e.g., specific to self Aβ, tau, α-syn, etc.)
Activate a broad repertoire of Th cells providing broad coverage of the targeted population with high MHC class II gene polymorphism
Preclinical Alzheimer's
Subtle changes in the brain, biomarkers in the cerebrospinal fluid and blood. No memory problems or other symptoms yet.
Subtle changes in the brain, biomarkers in the cerebrospinal fluid and blood. No memory problems or other symptoms yet.
Mild cognitive impairment
Changes in memory and other cognitive functions, like problem solving and judgment, but not enough to affect daily functioning.
Changes in memory and other cognitive functions, like problem solving and judgment, but not enough to affect daily functioning.
Moderate dementia
Unable to recall a major relevant aspect of their current life, an address or telephone number of many years, or the names of close family members.
Unable to recall a major relevant aspect of their current life, an address or telephone number of many years, or the names of close family members.
Severe dementia
Occasionally forgets the name of the spouse or caregiver on whom he or she is entirely dependent
Occasionally forgets the name of the spouse or caregiver on whom he or she is entirely dependent
75 — 85 years old
Our objective is a vaccine that produces high antibody titers, capable of breaching the blood-brain barrier to prevent harmful brain plaques and oligomers, while preserving normal brain function.
Our treatment strategy is to generate and keep effective and efficient levels of antibodies in the brain that halts significantly postpone the onset of the disease